Altamira Therapeutics Ltd (CYTO)

Name: Altamira Therapeutics Ltd (CYTO) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Altamira Therapeutics Ltd (CYTO)

Stock Card

$0.13

$0.01 (10.18%)

As on 17-Jan-2025 09:30EDT

Market cap

$1 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

0.2

P/B Ratio

0.1

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Altamira Therapeutics (CYTO) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.10 High: 0.14

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-11 Mln
ROE

-3.7 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.5
Debt to Equity

0
Book Value

$--
EPS

$--
Face value

--
Shares outstanding

3,778,520

10 Years Aggregate

CFO

CHF-162.11 Mln

EBITDA

CHF-175.19 Mln

Net Profit

CHF-180.48 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Altamira Therapeutics (CYTO)	10.2	-68.5	-78.1	-95.1	-94.2	-81.7	-76.9
BSE Sensex^*	-9.6	-2.7	2.9	-5.0	5.4	5.7	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 17-Jan-2025 | *As on 04-Sep-2026 | #As on 26-Oct-2023

Company	2023	2022	2021	2020	2019	2018	2017
Altamira Therapeutics (CYTO)	-96.4	-86.6	-30.7	61.7	255.3	-22.7	-44.8
S&P Small-Cap 600	13.9	-17.4	25.3	9.6	20.9	-9.7	11.7
BSE Sensex	18.7	4.4	22.0	15.8	14.4	5.9	27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Altamira Therapeutics (CYTO)

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic... acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda. Read more

Founder, President, Chairman, CEO & MD

Dr. Thomas Meyer Ph.D.
Founder, President, Chairman, CEO & MD

Dr. Thomas Meyer Ph.D.
Headquarters

Hamilton
Website

https://altamiratherapeutics.com

FAQs for Altamira Therapeutics (CYTO)

What is the current share price of Altamira Therapeutics Ltd (CYTO) Today?

The share price of Altamira Therapeutics Ltd (CYTO) is $0.13 (NASDAQ) as of 17-Jan-2025 09:30 EDT. Altamira Therapeutics Ltd (CYTO) has given a return of -94.15% in the last 3 years.

What is the current PB & PE ratio of Altamira Therapeutics Ltd (CYTO)?

The P/E ratio of Altamira Therapeutics Ltd (CYTO) is 0.16 times as on 17-Jan-2025.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2023	--	--
2022	--	--
2021	--	--
2020	--	--
2019	--	--

What is the 52 Week High and Low of Altamira Therapeutics Ltd (CYTO)?

The 52-week high and low of Altamira Therapeutics Ltd (CYTO) are Rs -- and Rs -- as of 07-Sep-2026.

What is the market cap of Altamira Therapeutics Ltd (CYTO)?

Altamira Therapeutics Ltd (CYTO) has a market capitalisation of $ 1 Mln as on 17-Jan-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Altamira Therapeutics Ltd (CYTO)?

Before investing in Altamira Therapeutics Ltd (CYTO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.